Development of Taste Masked Oral Formulation of Desloratadine

Rajat Pawar*, Chanchal Navin Raj

1*Research Scholar, Sunrise University, Bagad Rajput, Alwar, Rajasthan, 301028, India
2 Sunrise University, Bagad Rajput, Alwar, Rajasthan, 301028, India

ABSTRACT:

Mouth dissolving film is a novel dosage form which disintegrates in mouth within seconds with rapid onset of action and most convenient for oral route of administration. Patient compliance will be impediment for bitter drugs become unpleasant unless taste masked. Desloratadine is an antihistaminic and often prescribed for elderly and children hence the objective of this study is to develop a pleasant, patient friendly mouth dissolving film with superior patient compliance. Taste masking of desloratadine was done with resin complexation. The taste masked complex was formulated as mouth dissolving film. Superior product performance characteristics were observed in terms of disintegration time, vitro drug release all remained stable during the stability trial a laboratory scale up was performed to ensure the feasibility of commercial manufacturing.

Keywords: Desloratadine, Bitter taste, Complexation, stability, antihistaminic, Mouth dissolving film

1. INTRODUCTION:

Among the different routes of administration, the oral route of administration continues to be most preferred route due to various advantages including ease of administration, avoidance of pain, versatility and most importantly patient compliance. Many patients especially geriatric and paediatric have difficulty to swallow the tablets and hard gelatin capsules.1 Fast dissolving drug delivery systems (FDDDS) were developed as an alternative to tablet, capsule and syrups. Oral fast dissolving film is relatively a new dosage form in which thin film is prepared using hydrophilic polymers, which rapidly disintegrate or dissolve on tongue or in the buccal cavity. Oral administration is the most popular route due to ease of ingestion, pain avoidance, versatility (to accommodate various types of drug candidates), and most importantly, patient compliance. But the most evident drawback of oral dosage forms like tablets and capsules are difficulty in swallowing, leading to patient’s incompliance particularly in case of pediatric and geriatric, bedridden, nauseous patients. Fast dissolving drug delivery systems (FDDDS) were developed as an alternative to tablet, capsule and syrups.2 These systems consist of the solid dosage forms that disintegrate and dissolve quickly in the oral cavity without the administration of water. Rapid-dissolving oral thin film is a solid dosage form, which disintegrate or dissolve within 1 min when placed in the mouth without drinking of water or chewing. After disintegrating in mouth, enhanced the clinical effect of drug through pre-gastric absorption from mouth pharynx and oesophagus as the saliva passes down into the stomach. In such cases, bioavailability of drug is significantly greater than those observed from conventional tablet dosage form3

Allergic rhinitis (AR) is allergen driven immune mediated disorder characterized by nasal congestion, nasal pruritus, rhinorrhea, and sneezing. Traditionally, AR is classified as Seasonal or Perennial. According to Allergic Rhinitis and its Impact on Asthma guidelines, AR can be broadly classified into intermittent (≤4 days/week or ≤4 weeks/year) or persistent (>4 days/week or >4 weeks/year).4 Exhaustive literature survey shows that about 40% of the children are suffering from AR, but still these figures seem conservative as AR is often confused with common cold by physicians. Desloratadine (DSL), a descarboethoxy derivative of loratadine, is a second generation anti histaminic drug approved by FDA for paediatric usage. It is given as dose of 1.25 mg for children aged 2–5 years, that is, preschool children and 2.5 mg for children aged 6–11 years.5

2. MATERIALS AND METHOD:

Materials: Desloratadine was obtained as Zydus Cadila Health Care Pvt. Ltd., Indion 204, Indion 234, HPMC E-5, PVA, Sodium CMC, PEG-400, and Sodium saccharin, Citric acid was obtained from loba chemicals.

Purification of Ion-Exchange Resin:

Ion exchange resin has to be purified so that the contaminants caused by production on an industrial scale could be eliminated. Under magnetic stirring, 10 grams of wet resin were rinsed with 3 to 5 milliliters of deionized water, 50 milliliters of 95% ethanol, and 50 milliliters of deionized water to purify it. Resin was recovered through vacuum filtering after being rinsed with 60 ml of 2M NaOH, 60 ml of 2M HCl and deionized water at each
step. Dried after being washed in deionized water. Put through sieve 100 to get particles of the same size.1

Preparation of Drug Resin Complex (Resinate)

Complexation with ion exchange resins, such as Indion 234 and Indion 204, is used to hide the taste of Desloratadine. A batch procedure was used to make the resinate. Slurry composed of ion exchange resin and deionized water was created. The polymer structure was allowed to expand equally by stirring the mixture on a magnetic stirrer. The medication was diluted in 100 ml of distilled water and added to the resin slurry, which was then agitated constantly for 24 hours until equilibrium was reached. To eliminate any uncomplexed medication, the resulting resinate was filtered using Whatman filter paper No. 42 and rinsed with a large volume of deionized water. The drug concentration was then measured spectrophotometrically after drying at 50°C for 1 hour in a tray drier.3

Effect of Polymer: Drug Ratio on Drug Loading

Resin was used to create four batches of drug-resin at various concentrations (1:1, 1:2, 1:3, and 1:4). Drug concentration in loading solution was evaluated by spectrophotometry at 241 nm using 0.1N HCl as a blank after 3 hours of stirring. The blank solution was filtered through Whatman filter paper No. 42.

Effect of pH on Drug Loading

We made two solutions, each with around 1 gram of medication in 100 milliliters of water. Solutions were made with a pH range of 3.5, 5.0, 6.0, 7.0, and 8.0. After adding the resin (3g), the solution was agitated for three hours using a magnetic stirrer. The residual drug content in the loading solution was measured by spectrophotometry at 241 nm after the resinate was filtered through Whatman filter paper No. 42 using 0.1N HCl as a blank.

Effect of Temperature on Drug Loading

Solutions containing the drug and resin in the optimal ratio, kept at the optimal pH, and swirled on a magnetic stirrer at room temperature 30 °C, 40 °C, 50 °C, and 60 °C were used in the investigation. Using Whatman filter paper No. 42 and deionized water, resinate were filtered after 3 hours. Using 0.1N HCl as a blank, the residual drug content in the loading solution was calculated using spectrophotometry at 241 nm.

Determination of Drug Content in the Resinate

After carefully measuring out 100 mg of resinate, 90 minutes were spent mixing it with 100 ml of 0.1N HCl to get the drug's equivalent. After further diluting the solution with 0.1N HCl as a blank, the drug concentration was measured spectrophotometrically at 241 nm. The suspension was filtered using Whatman filter paper No. 42.

Characterization of DPC

Fourier Transform Infra-Red (FTIR) : Desloratadine, Indion 234, Indion 204, and the drug-polymer complex were all analyzed utilizing an FTIR - 8300 model, shimadzu, to collect their respective infrared spectra. The spectra were acquired from 4000 to 400 cm⁻¹ after the pellets were manufactured on a KBr press. The acquired spectra were compared to reference spectra to verify the correct drug/excipient identification.

Differential Scanning Calorimetry (DSC) : Differential scanning calorimeter (Perkin-Elmer, Pyris-I, MA, USA) readings were captured. Aluminum pans containing 5 mg samples were sealed and heated to 250 °C at a rate of 10 °C/min. Indium was used in the equipment's calibration process. The samples were heated between 50°C to 250 °C. If more heating to 250 degrees Celsius was needed, cooling to -10 degrees Celsius was used first.

Procedure of Mouth dissolving film Preparation: Solvent casting is the preferred process for creating mouth dissolving films because it allows for the dissolution of water-soluble components into a clear, viscous solution. A suitable solvent is used to dissolve the medication and any excipients. The two solutions are combined, agitated, and then cast onto the prepared Petri dish, which is then dried Solvent casting was used to create the optimal mouth dissolving dosage form of desloratadine the excipients were dissolved in distilled water and then put into the Petri dish after being well mixed.
Table 1: Formulation of Mouth dissolving film Using HPMC E5

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>A1</th>
<th>A2</th>
<th>A3</th>
<th>A4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug: resin complex Desloratadine:Indion-204 (Equivalent to 5 mg Desloratadine) gm</td>
<td>0.960</td>
<td>0.960</td>
<td>0.960</td>
<td>0.960</td>
</tr>
<tr>
<td>HPMC E-5 (%)</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>PEG-400 (ml)</td>
<td>0.12</td>
<td>0.24</td>
<td>0.36</td>
<td>0.48</td>
</tr>
<tr>
<td>Citric acid (gm)</td>
<td>0.31</td>
<td>0.31</td>
<td>0.31</td>
<td>0.31</td>
</tr>
<tr>
<td>Sodium saccharin (gm)</td>
<td>0.11</td>
<td>0.11</td>
<td>0.11</td>
<td>0.11</td>
</tr>
<tr>
<td>Water (ml)</td>
<td>qs</td>
<td>qs</td>
<td>qs</td>
<td>qs</td>
</tr>
</tbody>
</table>

Evaluation of Mouth dissolving film of Desloratadine:

**Determination of Weight Variation:** The films were measured and sliced into (2×2 cm²) Electronic balance was used to figure out the difference in weight.

**Thickness:** A micrometer screw gauge may be used to precisely measure it at several predetermined points. This is crucial for ensuring consistent dosing in the strip by measuring film thickness uniformly.

**Folding Endurance:** To test the strip's folding durability, fold it over and over again at the same spot until it snaps. The folding endurance of a film is measured by counting the number of folds it can withstand before tearing.

**In-vitro Disintegration Studies:** The film's disintegration and dissolution properties might be inferred from its disintegration time. The film used in this experiment measured exactly (2×2 cm²) and was put in a beaker containing 10 milliliters of artificial saliva. The in vitro disintegration time was recorded as the amount of time the film took to shatter.

**Determination of Drug Content:** Desloratadine concentration was calculated by dissolving sheets of known area (2×2 cm²) in 0.1 N HCl. Absorbance at 241 nm (using a UV-VIS double beam spectrophotometer) was used to quantify the concentration of desloratadine in the sample. An R² = 0.997 standard calibration curve of 0.1N HCl was used to calculate the drug concentration.

**In-vitro Dissolution Studies:** 0.1N HCl was also used in the dissolving test. After that, we put each film sample (equal to 5mg of medication) into the dissolving medium. 37±0.5°C At, 50 rpm, and with 900 ml of each dissolving media, a dissolution study was conducted using a tablet dissolution USP (XXI)/(XXII)(Electrolab). Using a spectrophotometer set at 241 nm (UV-VIS)\[14,15\]

3. RESULTS AND DISCUSSION:

**Characterization of Drug and resins**

**FTIR of Drug, Resins and Resinate:**

FTIR spectroscopy was used to investigate how desloratadine interacted with the excipients included in the formulations. The KBr press was used to produce the pellets for the FTIR analysis. The spectra were collected from 4-400 cm⁻¹, which is a range of wave numbers. Infrared spectra of desloratadine showed many prominent peaks, including those at 3324.64 (3300-3400) cm⁻¹ (N-H) stretching of 2-amine, 1704.73 (1665-2000) cm⁻¹ (C=O), 1279 cm⁻¹ (C-N) stretching of tertiary amine, and 727.11 (600-800) cm⁻¹ (C-CL) stretching in the benzene ring. DRC's lack of peaks at 1705 cm⁻¹ and 1279 cm⁻¹ shows that drug and resin have formed a complex. The absence of the 3297.90 cm⁻¹ peak in DRC corresponding to -OH stretching indicates that the amino group of the medication interacts with the carboxyl group of the resin during DRC synthesis.
Differential Scanning Calorimetry (DSC)

DSC analysis was performed on the samples by the Japanese company Shimadzu. The samples were stored in an aluminum container that had been cut open. Research was conducted at a heating rate of 10 degrees Celsius per minute in a static air environment with temperatures ranging from 50°C to 250°C. After comparing to a standard, the maximum temperatures were calculated. Desloratadine's melting point, as shown on a DSC thermogram, corresponds to an endothermic peak at 151°C. An interaction between the medication and the resin was indicated by an endothermic peak in the melting temperature of the resin at 162°C with the peak intensity decreasing as the melting temperature increased.
Optimization of Drug Loading for Indion-204

- The preparation of drug-resinate was perfected by adjusting the pH and temperature during the sorption process and the percentage of drug-resin used. Experiments were conducted using the cation exchange resins Indion-234 and Indion-204 for batch loading.

- In under three hours, using Indion 204, a 96.83% drug-resin combination was produced at a 1:3 ratio.

- After using the optimal ratio at pH levels between 4.2 and 8, including 5, 6, 7, and 8. The highest percentage of complex formation was found at a pH of 7.7 compared to the other pH values considered. Evidence suggests no drug-resin compound was formed in an acidic environment.

- After using the ideal ratio and pH at temperatures of 30, 40, 50, and 60 degrees The highest percentage of complex production occurs at a temperature of 40 degrees Celsius, when 98.56 percent of complexes are created.

Table: 2 Amount of complexed drug of different drug to resin (Indion 204) ratio

<table>
<thead>
<tr>
<th>Drug: Resin Ratio</th>
<th>Time (hrs.)</th>
<th>Free Drug (%)</th>
<th>Complexation Efficiency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:1</td>
<td>3</td>
<td>34.00</td>
<td>64.00</td>
</tr>
<tr>
<td>1:2</td>
<td>3</td>
<td>01.00</td>
<td>94.55</td>
</tr>
<tr>
<td>1:3</td>
<td>3</td>
<td>00.75</td>
<td>96.83</td>
</tr>
<tr>
<td>1:4</td>
<td>3</td>
<td>01.25</td>
<td>94.71</td>
</tr>
</tbody>
</table>

Table: 3 Amount of complexed drug of different drug to resin (Indion 234) ratio

<table>
<thead>
<tr>
<th>Drug: Resin Ratio</th>
<th>Time (hrs.)</th>
<th>Free Drug (%)</th>
<th>Complexation Efficiency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:1</td>
<td>3</td>
<td>46.00</td>
<td>51.00</td>
</tr>
<tr>
<td>1:2</td>
<td>3</td>
<td>09.00</td>
<td>86.00</td>
</tr>
<tr>
<td>1:3</td>
<td>3</td>
<td>03.00</td>
<td>92.31</td>
</tr>
<tr>
<td>1:4</td>
<td>3</td>
<td>04.00</td>
<td>93.27</td>
</tr>
</tbody>
</table>
Figure: 3 Chart for amount of complexed drug of different drug to resin (Indion 234 & Indion 234) ratio

Table: 4 Amount of complexed drug for different times of mixing using Indion 204

<table>
<thead>
<tr>
<th>Drug: Resin Ratio</th>
<th>Time (hrs.)</th>
<th>Free Drug (%)</th>
<th>Complexation Efficiency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:3</td>
<td>3</td>
<td>0.79</td>
<td>96.55</td>
</tr>
<tr>
<td>1:3</td>
<td>4</td>
<td>0.77</td>
<td>96.61</td>
</tr>
<tr>
<td>1:3</td>
<td>5</td>
<td>0.75</td>
<td>96.79</td>
</tr>
<tr>
<td>1:3</td>
<td>6</td>
<td>64.75</td>
<td>34.68</td>
</tr>
<tr>
<td>1:3</td>
<td>7</td>
<td>0.64</td>
<td>97.35</td>
</tr>
<tr>
<td>1:3</td>
<td>8</td>
<td>0.60</td>
<td>97.35</td>
</tr>
</tbody>
</table>

Table: 5 Amount of complexed drug for different pH using Indion 204

<table>
<thead>
<tr>
<th>pH</th>
<th>Drug: Resin Ratio</th>
<th>Time (hrs.)</th>
<th>Free Drug (%)</th>
<th>Complexation Efficiency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.2</td>
<td>1:3</td>
<td>3</td>
<td>64.75</td>
<td>34.68</td>
</tr>
<tr>
<td>5</td>
<td>1:3</td>
<td>3</td>
<td>58.37</td>
<td>41.63</td>
</tr>
<tr>
<td>6</td>
<td>1:3</td>
<td>3</td>
<td>11.73</td>
<td>88.26</td>
</tr>
<tr>
<td>7</td>
<td>1:3</td>
<td>3</td>
<td>09.26</td>
<td>90.73</td>
</tr>
<tr>
<td>8</td>
<td>1:3</td>
<td>3</td>
<td>10.65</td>
<td>87.35</td>
</tr>
</tbody>
</table>
Figure : 4 Graph showing the effect of pH on Complexation efficiency

Table: 6 Amount of complexed drug for different temperature using Indion 204

<table>
<thead>
<tr>
<th>Temperature</th>
<th>Drug: Resin Ratio</th>
<th>Time (hrs.)</th>
<th>Free Drug (%)</th>
<th>Complexation Efficiency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>30° C</td>
<td>1:3</td>
<td>3</td>
<td>02.54</td>
<td>97.46</td>
</tr>
<tr>
<td>40° C</td>
<td>1:3</td>
<td>3</td>
<td>01.43</td>
<td>98.56</td>
</tr>
<tr>
<td>50° C</td>
<td>1:3</td>
<td>3</td>
<td>07.05</td>
<td>91.95</td>
</tr>
<tr>
<td>60° C</td>
<td>1:3</td>
<td>3</td>
<td>14.76</td>
<td>83.21</td>
</tr>
</tbody>
</table>

Figure: 5 Graph showing the effect of temperature on Complexation efficiency
Formulation of mouth dissolving film:

Figure: 6 Desloratadine mouth dissolving film in petridish

Figure: 7 Desloratadine Mouth dissolving film in cutted 2x2 cm²

Table: 7 Evaluation data of Mouth dissolving film of Desloratadine:

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Weight variation (mg) Mean±SD</th>
<th>Thickness (mm) Mean±SD</th>
<th>Folding endurance (Times) Mean±SD</th>
<th>Drug Content (%) Mean±SD</th>
<th>Disintegration Time (sec) Mean±SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>10.03 ± 0.17</td>
<td>0.052± 0.005</td>
<td>410.00 ± .29</td>
<td>99.56±0.57</td>
<td>7.61 ± 0.48</td>
</tr>
<tr>
<td>F2</td>
<td>12.18 ± 0.12</td>
<td>0.057±0.016</td>
<td>420.33 ± 2.45</td>
<td>98.51 ± .79</td>
<td>10.66 ± 0.47</td>
</tr>
<tr>
<td>F3</td>
<td>12.76 ± 0.25</td>
<td>0.060±0.008</td>
<td>434.00 ± .28</td>
<td>98.19 ± .74</td>
<td>12.22 ± 0.58</td>
</tr>
<tr>
<td>F4</td>
<td>12.46 ± 0.11</td>
<td>0.058±0.019</td>
<td>424.00 ± 4.23</td>
<td>98.42 ± .11</td>
<td>10.93 ± 0.13</td>
</tr>
</tbody>
</table>
In-vitro dissolution study of mouth dissolving film of Desloratadine:

![In vitro drug release study](image)

**Figure 8 In vitro drug Release study**

**Stability study:** The result of stability study indicated that the drug product falls well within the proposed stability specification. The data showed that there is no significant physical or chemical change indicating that the formulation would maintain its efficacy and quality throughout its proposed shelf life.

4. CONCLUSION:

The formulation and evaluation of mouth dissolving films (MDFs) of Desloratadine have gained significant attention due to their potential benefits such as improved patient compliance, rapid onset of action, and ease of administration. Use of cation exchange resins offers good method for preparing bitterless desloratadine formulation using drug-resin complex. The drug is dispersed in purified water under stirring at 100rpm in room temperature. The pH of the drug dispersion is adjusted to pH 6.5±0.5 with 2% citric acid solution. The resin is then added to the pH adjusted drug dispersion and stirred for 3 hours. Use of cation exchange resins offers good method for preparing bitterless desloratadine formulation using drug-resin complex.

ACKNOWLEDGMENT:

The authors are grateful to the management and staff of Sunrise University, Alwar, Rajasthan, and Department of Pharmaceutics for providing facilities and encouragement.

REFERENCES:


